Changes in the Levels of Modern Biomarkers in Patients with Decompensated Heart Failure After Myocardial Infarction Under the Influence of Treatment with Succinic Acid and Arginine Preparations
PDF

Keywords

decompensated heart failure
B-type brain natriuretic peptide
ST2
succinic acid
arginine preparations

Abstract

The prevalence of heart failure in Europe and worldwide is high. This syndrome is a common cause of hospitalization and has a significant impact on morbidity, mortality and healthcare costs in highly developed countries. The study of biomarkers in heart failure is of wide interest as they can improve diagnosis, predict the development of heart failure and its decompensation, and help in assessing treatment outcomes.            The objective of the research was to study the feasibility of using multiple biomarker strategy for diagnosing decompensated heart failure in the post-infarction period and to assess changes in these markers after treatment with succinic acid and arginine preparations.          Materials and Methods. There were examined 120 patients with Q-QS wave and non-Q wave myocardial infarction complicated by decompensated heart failure. All the patients were divided into 2 groups (depending on Q-QS wave and non-Q wave myocardial infarction) and 4 subgroups (depending on rehabilitation therapy) being homogenous by age and gender.   Results. When studying the dynamics of changes in blood level of N-terminal pro-B-type brain natriuretic peptide and ST2, there was observed its significant reduction in all the patients with prior Q-QS wave myocardial infarction complicated by decompensated heart failure after treatment. The most significant changes were observed in the patients of Group IV who, on the background of basic therapy, received succinic acid and arginine preparations according to the proposed scheme. The combined use of arginine preparations and succinic acid in combination therapy for decompensated heart failure secondary to prior Q-QS wave myocardial infarction allowed reducing blood levels of N-terminal pro-B-type brain natriuretic peptide under conditions of graded exercises. Similar tendencies were observed when determining this indicator in the patients with non-Q wave myocardial infarction complicated by decompensated heart failure after rehabilitation treatment.    Conclusions. The use of succinic acid and arginine preparations when treating the patients with prior Q-QS wave and non-Q wave myocardial infarction complicated by decompensated heart failure allowed us to significantly reduce the level of immunological enzymes such as N-terminal pro-B-type brain natriuretic peptide and ST2, which indicate the presence and development of decompensated heart failure after myocardial infarction.
https://doi.org/10.21802/gmj.2019.4.1
PDF

References

Maisel AS, Richards AM, Pascual-Figal D et al. Serial ST2 testing in hospitalized patients with acute heart failure. Am J Cardiol. 2015;115(7):32B-37B. DOI: https://doi.org/10.1016/j.amjcard.2015.01.038 [PMid:25682437]

Nishimura M, Brann A, Chang K-W et al. The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers. Curr Heart Fail Rep. 2018;15(4):239-249. DOI: https://doi.org/10.1007/s11897-018-0398-4 [PMid:29987498]

Pascual-Figal DA, Januzzi JL. The Biology of ST2: The International ST2 Consensus Panel. Am J Cardiol. 2015;115(7):3B-7B. DOI: https://doi.org/10.1016/j.amjcard.2015.01.034 [PMid:25665766]

Maisel AS, Di Somma S. Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2). Eur Heart J. 2016;0:1-9. DOI: https://doi.org/10.1093/eurheartj/ehw462 [PMid:28028009]

Maisel AS, Richards AM, Pascual-Figal D et al. Serial ST2 Testing in Hospitalized Patients With Acute Heart Failure. Am J Cardiol. 2015;115:32B-37B. DOI: https://doi.org/10.1016/j.amjcard.2015.01.038 [PMid:25682437]

Ibrahim N, Januzzi JL. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev Cardiovasc Ther. 2015;13(9):1017-1030. DOI: https://doi.org/10.1586/14779072.2015.1071664 [PMid:26198476]

Ponikowski P, Voors A, Anker S et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-3200. DOI: https://doi.org/10.1093/eurheartj/ehw128 [PMid:27206819]

Roberts E, Ludman A, Dworzynski K et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. Br Med J. 2015;350:h910. DOI: https://doi.org/10.1136/bmj.h910 [PMid:25740799 PMCid:PMC4353288]

Gaggin H, Januzzi J. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832:2442-2450. DOI: https://doi.org/10.1016/j.bbadis.2012.12.014 [PMid:23313577]

Lopes D, Menezes Falcão L. Mid-regional pro-adrenomedullin and ST2 in heart failure: contributions to diagnosis and prognosis. Rev Port Cardiol. 2017;36(6):465-472. DOI: https://doi.org/10.1016/j.repc.2016.11.009 [PMid:28606358]

Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57-70. DOI: https://doi.org/10.1016/j.cca.2014.09.021 [PMid:25269091]

Fan PC, Chang CH, Chen YC. Biomarkers for acute cardiorenal syndrome. Nephrology (Carlton). 2018;23:68-71. DOI: https://doi.org/10.1111/nep.13473 [PMid:30298648]

Juan W, Guo-Juan T, Li-Na H et al. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14:135-150.

Yancy CW, Jessup M, Bozkurt B et al, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-e239. DOI: https://doi.org/10.1016/j.jacc.2013.05.019 [PMid:23747642]

O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78-e140. DOI: https://doi.org/10.1161/CIR.0b013e3182742cf6 [PMid:23247304]

Von Lueder TG, Krum H. New medical therapies for heart failure. Nat Rev Cardiol. 2015;12:730-740. DOI: https://doi.org/10.1038/nrcardio.2015.137 [PMid:26416006]

Gaggin HK, Szymonifka J, Bhardwaj A et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2:65-72. DOI: https://doi.org/10.1016/j.jchf.2013.10.005 [PMid:24622120]

Lupu S, Agoston-Coldea L. Soluble ST2 in Ventricular Dysfunction. Adv Clin Chem. 2015;69:139-159. DOI: https://doi.org/10.1016/bs.acc.2014.12.005 [PMid:25934361]

Dieplinger B, Januzzi Jr, Steinmair M et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - the Presage ST2 assay, Clin Chim Acta. 2009;409:33-40. DOI: https://doi.org/10.1016/j.cca.2009.08.010 [PMid:19699192]

Lu J, Snider JV, Grenache DJ. Establishment of reference intervals for soluble ST2 from a United States Population. Clin Chim Acta. 2010;411:1825-1826. DOI: https://doi.org/10.1016/j.cca.2010.07.014 [PMid:20654603]

Richards AM. ST2 and prognosis in chronic heart failure. J Am Coll Cardiol. 2018;72(19):2321-2323. DOI: https://doi.org/10.1016/j.jacc.2018.08.2164 [PMid:30384888]

Savic-Radojevic A, Pljesa-Ercegovac M, Matic M et al. Novel Biomarkers of Heart Failure. Adv Clin Chem. 2017;79:93-152. DOI: https://doi.org/10.1016/bs.acc.2016.09.002 [PMid:28212715]

Khan SQ, O'Brien RJ, Struck J et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2007;49:1525-1532. DOI: https://doi.org/10.1016/j.jacc.2006.12.038 [PMid:17418290]

Tschöpe C, van Linthout S, Kherad B. Heart failure with preserved ejection fraction and future pharmacological strategies: a glance in the crystal ball. Curr Cardiol Rep. 2016;19(8):70. DOI: https://doi.org/10.1007/s11886-017-0874-6 [PMid:28656481]

Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368-378. DOI: https://doi.org/10.1038/nrcardio.2016.25 [PMid:26935038 PMCid:PMC4868779]

Lundgren J, Sandqvist A, Hedeland M et al. Alterations in plasma L-arginine and methylarginines in heart failure and after heart transplantation. Scand Cardiovasc J. 2018;52(4):196-204. DOI: https://doi.org/10.1080/14017431.2018.1459823 [PMid:29648475]

Lundgren J, Soderlund C, Radegran G. Impact of postoperative pulmonary hypertension on outcome after heart transplantation. Scand Cardiovasc J. 2017;51:172-181. DOI: https://doi.org/10.1016/j.jtcvs.2011.02.028 [PMid:21596173 PMCid:PMC3244079]

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Downloads

Download data is not yet available.